Amphastar Pharmaceuticals (AMPH) EBIT (2013 - 2026)

Amphastar Pharmaceuticals' EBIT history runs 14 years deep, the most recent figure standing at $13.6 million for Q1 2026.

• In Q1 2026, EBIT fell 63.45% year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $2.3 million (down 98.82% YoY), while the FY2025 annual figure was $26.0 million, down 87.36% from the prior year.
• EBIT was $13.6 million for Q1 2026 at Amphastar Pharmaceuticals, up from -$78.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $72.7 million in Q3 2023 to a low of -$78.8 million in Q4 2025.
• Historically, EBIT has averaged $32.3 million across 5 years, with a median of $37.3 million in 2025.
• The sharpest annual moves came in 2023 and 2025: EBIT soared 212.89% in 2023, then slumped 274.63% in 2025.
• A 5-year view of EBIT shows it stood at $37.8 million in 2022, then jumped by 42.68% to $54.0 million in 2023, then retreated by 16.37% to $45.1 million in 2024, then plunged by 274.63% to -$78.8 million in 2025, then jumped by 117.29% to $13.6 million in 2026.
• The last three EBIT figures came in at $13.6 million (Q1 2026), -$78.8 million (Q4 2025), and $25.3 million (Q3 2025), per Business Quant data.